Quantbot Technologies LP Purchases 1,131 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Quantbot Technologies LP increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 13.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,300 shares of the medical research company’s stock after acquiring an additional 1,131 shares during the period. Quantbot Technologies LP’s holdings in Charles River Laboratories International were worth $1,717,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Versant Capital Management Inc grew its stake in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the period. Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after buying an additional 115 shares during the last quarter. ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International in the fourth quarter worth about $56,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the third quarter worth about $59,000. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CRL. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Morgan Stanley dropped their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Bank of America decreased their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, UBS Group reaffirmed a “neutral” rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $189.77.

Insider Activity

In related news, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Trading Up 0.0 %

NYSE CRL opened at $167.29 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $273.57. The stock has a market cap of $8.55 billion, a P/E ratio of 1,115.28, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The stock has a 50 day simple moving average of $165.66 and a two-hundred day simple moving average of $183.49.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter in the previous year, the business posted $2.46 earnings per share. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).